Fertility Preservation Iatrogenic denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for FERTILITY PRESERVATION IATROGENIC are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Fertility Preservation (Iatrogenic) as "Not FDA-Approved"

Fertility preservation performed before gonadotoxic treatment — such as egg freezing, embryo cryopreservation, sperm banking, or ovarian tissue preservation — does not require FDA drug approval in the traditional sense, because the procedures themselves are surgical or laboratory-based rather than pharmaceutical. However, Aetna may categorize certain components of the fertility-preservation process (for example, specific stimulation protocols, hormonal agents used off-label, or newer laboratory methods) as lacking sufficient regulatory approval or clinical evidence under its own coverage criteria. This denial framing is often a mismatch between how the claim was coded and how Aetna's policy is written — and it is worth challenging.

## Why This Denial Is Appealable

Many fertility-preservation interventions are well-established in practice and are endorsed by major reproductive medicine and oncology guideline bodies. Aetna's medical policies are not law; they are internal coverage determinations that must be applied consistently and in good faith under both ERISA and, for marketplace or fully-insured plans, the ACA. A blanket "not FDA-approved" denial applied to a procedure — rather than a drug — is frequently a coding or category error that can be reversed.

## Federal Appeal Framework

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or ACA §2719 (fully-insured and marketplace plans). Submit within the timeframe shown on your Explanation of Benefits (typically 180 days).
• External review: If the internal appeal is denied, you may request an independent external review within approximately four months of that denial. An accredited Independent Review Organization (IRO) will evaluate the clinical merits without deference to Aetna's initial decision.
• Expedited review: If the treatment is time-sensitive — for example, you must begin chemotherapy within weeks — request an expedited internal appeal and expedited external review simultaneously. Decisions are typically required within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Pathology report, oncology or specialist notes confirming the underlying condition requiring gonadotoxic treatment.
• Treatment plan: Oncologist's written treatment plan showing the specific gonadotoxic agents or radiation fields involved and their expected impact on fertility.
• Prescriber medical-necessity letter: A letter from your reproductive endocrinologist AND your treating oncologist, together explaining why fertility preservation is medically necessary prior to treatment, referencing applicable guideline organization recommendations (e.g., ASCO oncofertility guidelines, ASRM practice committee opinions).
• Prior-treatment and timing context: Documentation showing the preservation must occur before — not after — the gonadotoxic treatment begins.
• Policy language: Obtain Aetna's current published coverage policy for fertility preservation (available on Aetna's website). Identify every listed coverage criterion.

## Criteria-Mapping Structure

Build a table in your appeal letter with three columns:

| Aetna Coverage Requirement | Source (Label / Policy Section) | How Your Chart Meets It | |---|---|---| | [Copy each requirement verbatim from Aetna's policy] | [Policy name and section number] | [Exact chart fact, date, and note reference] |

Address the specific procedure or agent flagged as "not approved," citing its established-use status per ASRM or ASCO guidance. If the denial targets a specific drug, obtain the FDA-approved prescribing label and confirm whether the use is on-label; if off-label, document that the applicable guideline organization endorses it for this indication.